MGNX vs REA Comparison

Macrogenics Inc is a clinical-stage biopharmaceutical company focused on developing antibody-based therapeutics for the treatment of cancer. The company is currently developing therapeutics utilizing multiple modalities, including antibody-drug conjugates (ADCs) and multi-specific antibodies (which it refers to as DART and TRIDENT molecules). It is advancing three proprietary product candidates in clinical development: lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload, and MGC028, an ADC that targets ADAM9 and delivers a novel TOP1i-based linker-payload. Its segment is developing and commercializing monoclonal antibody-based therapeutics.

Rare Earths Americas Inc is an exploration stage company focused on advancing projects related to rare earth minerals. Its activities include evaluating mineralization and assessing the characteristics and economic potential of its assets. Its portfolio includes the Shiloh Project in Georgia, United States; the Alpha Project in Bahia, Brazil; and the Constellation Project in Minas Gerais, Brazil. It also holds additional early-stage exploration projects, including the Homer Project in Goiás, Brazil, and the Liberty Peak Project in Georgia, United States. The company has two reportable segments due to their geographical location: United States Mining Operations and Brazil Mining Operations.